山东大学学报(医学版) ›› 2017, Vol. 55 ›› Issue (4): 82-85.doi: 10.6040/j.issn.1671-7554.0.2016.283
李安, 陈丰哲,王正,孟祥珠,许楠楠,马立宪
LI An, CHEN Fengzhe, WANG Zheng, MENG Xiangzhu, XU Nannan, MA Lixian
摘要: 目的 评估西他沙星、头孢哌酮/舒巴坦(1∶1)和多黏菌素E单药及联合用药对泛耐药鲍曼不动杆菌的体外抗菌活性。 方法 从临床中分离得到22株泛耐药鲍曼不动杆菌。单一用药时,微量肉汤稀释法测定3种抗生素对泛耐药鲍曼不动杆菌的最低抑菌浓度(MIC)。联合用药时,棋盘稀释法测定MIC,并分别计算部分抑菌浓度(FIC)及部分抑菌浓度指数(FICI)判定联合效应。 结果 单一用药时,西他沙星的MIC为0.25~16 μg/mL;头孢哌酮/舒巴坦(1∶1)的MIC为4.0/4.0 μg/mL~128/128 μg/mL;多黏菌素E的MIC为 0.5~8.0 μg/mL。两两联合用药时,3种药物的MIC均降低。 结论 西他沙星、头孢哌酮/舒巴坦(1∶1)和多黏菌素E 3种抗生素两两联合用药时,抗菌药物均表现出协同、部分协同或是相加的作用,药物联合应用没有表现出拮抗作用。
中图分类号:
[1] Cerqueira GM, Peleg AY. Insights into Acinetobacter baumannii pathogenicity[J]. IUBMB life, 2011, 63(12):1055-1060. [2] Howard A, ODonoghue M, Feeney A. Acinetobacter baumannii: an emerging opportunistic pathogen[J]. Virulence, 2012, 3(3):243-250. [3] Liu WP, Tian YQ, Hai YT, et al. Prevalence survey of nosocomial infections in the Inner Mongolia Autonomous Region of China[2012-2014] [J]. J Thorac Dis, 2015, 7(9):1650-1657. [4] 陈佰义, 何礼贤, 胡必杰, 等. 中国鲍曼不动杆菌感染诊治与防控专家共识[J]. 中华医学杂志, 2012, 92(2):76-85. [5] Roca I, Espinal P, Vila-Farrés X, et al. The Acinetobacter baumannii oxymoron: commensal hospital dweller turned pan-drug-resistant menace[J]. Front Microbiol, 2012, 3:148. doi:10.3389/fmicb.2012.00148. eCollection, 2012. [6] Magiorakos AP, Srinivasan A, Carey RB. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance[J]. Clin Microbiol Infect, 2012, 18(3): 268-281. [7] CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fifth Informational Supplement: CLSI Document M100-S25[S]. Wayne. PA: Clinical and Laboratory Standards Institute, 2015. http://www.clsi.org. [8] Thamlikitkul V, Tiengrim S. In vitro activity of sitafloxacin against carbapenem-resistant Acinetobacter baumannii[J]. Int J Antimicrob Agents, 2013, 42(3): 284-285. [9] European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 5.0[EB/OL].(2015-01-01)[2016-03-15]. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_5.0_Breakpoint_Table_01.pdf [10] Kiffer CR, Sampaio JL, Sinto S, et al. In vitro synergy test of meropenem and sulbactam against clinical isolates of Acinetobacter baumannii[J]. Diagn Microbiol Infect Dis, 2005, 52(4):317-322. [11] Alfandari S, Gois J, Delannoy PY, et al. Management and control of a carbapenem-resistant Acinetobacter baumannii outbreak in an intensive care unit[J]. Med Mal Infect, 2014, 44(5):229-231. [12] Ayraud-Thévenot S, Huart C, Mimoz O, et al. Control of multi-drug-resistant Acinetobacter baumannii outbreaks in an intensive care unit: feasibility and economic impact of rapid unit closure[J]. J Hosp Infect, 2012, 82(4):290-292. [13] Jean SS, Hsueh PR. High burden of antimicrobial resistance in Asia[J]. Int J Antimicrob Agents, 2011, 37(4):291-295. [14] Bean DC, Wigmore SM. Antibiotic tolerance and combination therapy[J]. MBio, 2015, 6(2):e00120. doi: 10.1128/mBio.00120-15. [15] Kempf M, Rolain JM. Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options[J]. Int J Antimicrob Agents, 2012, 39(2):105-114. [16] Viehman JA, Nguyen MH, Doi Y. Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections[J]. Drugs, 2014, 74(12):1315-1333. [17] Huang YS, Wang JT, Sheng WH, et al. Comparative in vitro activity of sitafloxacin against bacteremic isolates of carbapenem resistant Acinetobacter baumannii complex[J]. J Microbiol Immunol Infect, 2015,48(5): 545-551. |
[1] | 李陶1,李玉1,汪雯1,张帆2,顾腾振3. 碳青霉烯类药物联合舒巴坦或头孢哌酮对铜绿假单胞菌的药敏影响[J]. 山东大学学报(医学版), 2013, 51(8): 65-68. |
|